Endocrine-Sensitive Premenopausal Breast Cancer

Endocrine-Sensitive Premenopausal Breast Cancer

The Ups and Downs of Estrogen Suppression in Endocrine-Sensitive Premenopausal Breast Cancer

Not a member of My prIME? Join now for instant access.

Meeting Overview

Enhance your understanding of ovarian suppression in endocrine-sensitive breast cancer to provide optimal treatment that delivers favorable efficacy while minimizing toxicity. Along with short didactic lectures, this symposium will have an interactive case-based expert panel discussion facilitating a better understanding of how endocrine treatments for young women with estrogen receptor-positive disease need to be managed.

Official EBCC-11 Sponsored Satellite Symposium #EBCC11

Date and Location

Wednesday, 21 March 2018
13.45 – 15.00

Room: Goya (111)
Centre de Convencions Internacional de Barcelona (CCIB)
Plaça de Willy Brandt, 11-14
Barcelona, Spain



Wednesday, 21 March 2018
13.45 – 15.00



Barcelona, Spain



13.45 Welcome and clinical scenarios quiz
Michael Gnant, MD, FACS
13.55 Fertility preservation and impact of pregnancy in women with early breast cancer
Fedro Peccatori, MD, PhD
14.10 Questions and discussion
14.15 Exploiting the benefits of ovarian suppression in early breast cancer
Prue Francis, MD
14.35 Managing the downside of ovarian suppression
Michael Gnant, MD, FACS
14.45 Questions, faculty discussion, and review of clinical scenarios
14.55 Conclusions and prIME Points™
Michael Gnant, MD, FACS
15.00 Adjourn


  • Michael Gnant, MD, FACSUniversity of Vienna
    Vienna, Austria
  • Faculty

  • Prue Francis, MDPeter MacCallum Cancer Centre
    Melbourne, Australia
  • Fedro Peccatori, MD, PhDEuropean Institute of Oncology
    Milan, Italy

This educational activity is specifically designed for oncologists, breast surgeons, and other healthcare professionals interested in and/or involved in the treatment of breast cancer and who wish to understand some of the latest developments in endocrine treatments for young women with estrogen receptor-positive (ER+) disease.

After successful completion of this educational activity, participants should be able to:

  • Describe the latest data from clinical trials of endocrine treatment for premenopausal women with early breast cancer and identify those most likely to benefit from combined endocrine therapy that includes ovarian function suppression (OFS)
  • Show an awareness of the endocrine and skeletal side effects of OFS and strategies for their management
  • Summarize the available options for fertility preservation for premenopausal women with early breast cancer
  • Understand the impact of pregnancy on breast cancer outcomes

This educational activity is supported by Ipsen.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.


This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.